ejoxot.wordpress.com
On Thursday, Human Genome Sciences HGSI) announced it had submitted a Biologic License Application to the FDA for its humanj monoclonal antibodydrug ABthrax, also known as for the treatment of inhalation Human Genome Sciences said the submission showedx a survival benefit in studies of rabbitsw and monkeys and the results of safetu studies conducted in healthy human volunteers. “Based on the resultws of our efficacy andsafety studies, we believ e raxibacumab has the potential to be an importantg new treatment for inhalation anthrax," said Human Genomee Sciences Senior Vice President Sally The U.S.
government has already reached that In thefirst quarter, Human Genome Sciencews initiated delivery of 20,000 doses of raxibacumag to the U.S. Strategic National Stockpil for emergency use in the treatment ofinhalatioj anthrax, generating $127.8 million in product sales. Raxibacumab was developed under a contract enteresd into in 2006 with the Biomedical Advancef Research and Development Authority of the Office of the Assistan Secretary for Preparedness and Response ofthe U.S. Departmenty of Health and Human Services. Raxibacumab is the firsr product that Human Genome Sciencesa has submitted for a BiologicsLicense Application.
If it would mean a $10 milliohn milestone payment for Human Genome Sciences under termws of theHHS
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment